Key result
Aminopeptidase A deficiency in mice increased susceptibility to glomerular injury, leading to significant albuminuria and glomerulosclerosis following AngII infusion compared to wild-type controls.
Why the study?
Does deficiency of Aminopeptidase A increase susceptibility to glomerular injury in response to nephrotoxic serum or Angiotensin II infusion in mice?
Does deficiency of Aminopeptidase A increase susceptibility to glomerular injury in response to nephrotoxic serum or Angiotensin II infusion in mice?
Deficiency of Aminopeptidase A increases susceptibility to AngII-mediated glomerular injury, suggesting a protective role for APA in metabolizing AngII in the kidney.
Should not change practice; leaves open aminopeptidase A as a therapeutic target in AngII-driven glomerular disease.
Aminopeptidase A (APA) is expressed in glomerular podocytes and tubular epithelia and metabolizes angiotensin II (AngII), a peptide known to promote glomerulosclerosis. In this study, we tested whether APA expression changes in response to progressive nephron loss or whether APA exerts a protective role against glomerular damage and during AngII-mediated hypertensive kidney injury. At advanced stages of FSGS, fawn-hooded hypertensive rat kidneys exhibited distinctly increased APA staining in areas of intact glomerular capillary loops. Moreover, BALB/c APA-knockout (KO) mice injected with a nephrotoxic serum showed persistent glomerular hyalinosis and albuminuria 96 hours after injection, whereas wild-type controls achieved virtually full recovery. We then tested the effect of 4-week infusion of AngII (400 ng/kg per minute) in APA-KO and wild-type mice. Although we observed no significant difference in achieved systolic BP, AngII-treated APA-KO mice developed a significant rise in albuminuria not observed in AngII-treated wild-type mice along with increased segmental and global sclerosis and/or collapse of juxtamedullary glomeruli, microcystic tubular dilation, and tubulointerstitial fibrosis. In parallel, AngII treatment significantly increased the kidney AngII content and attenuated the expression of podocyte nephrin in APA-KO mice but not in wild-type controls. These data show that deficiency of APA increases susceptibility to glomerular injury in BALB/c mice. The augmented AngII-mediated kidney injury observed in association with increased intrarenal AngII accumulation in the absence of APA suggests a protective metabolizing role of APA in AngII-mediated glomerular diseases.
No takes yet. Share an insight, caveat, or question.
Velez et al. (2017) studied Glomerular injury. Aminopeptidase A (APA) deficiency vs. Wild-type controls was evaluated on Albuminuria and glomerular sclerosis. Aminopeptidase A deficiency in mice increased susceptibility to glomerular injury, leading to significant albuminuria and glomerulosclerosis following AngII infusion compared to wild-type controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: